Park Square has placed Laura Hamill as Independent Director at Y-mAbs Therapeutics, Inc.
| less than a minute read
Y-mAbs Announces Appointment of Laura J. Hamill to its Board of Directors
Get in touch
Get in touch
Y-mAbs Therapeutics, Inc., (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the Board of Directors (the “Board”) nominates healthcare executive Laura J. Hamill to be elected as a Class II director at the Company’s 2020 annual meeting of stockholders (the “Annual Meeting”).
Get in touch
Get in touch
Latest Insights
